Stifel on Viridian Therapeutic (VRDN): data 'disappointing at face,' but Elegrobart still potentially BIC

March 30, 2026 9:19 AM

Stifel analyst Alex Thompson reiterated a Buy rating and $48.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider